Degludec

Type: Product
Name: Degludec
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

GSK glimepiride/atorvastatin fixed dose combination tablet, which just completed Phase III clinical trials for diabetes

- Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market - a new market research report on companiesandmarkets.comDiabetes is a chronic progressive disease of the endocrine system in which, during the metabolism of carbohydrates, ... [Published PR inside - Apr 14 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

FDA: No Decision On CV Outcomes Trial For Afrezza

Afrezza Review Shows Need For Patient-Driven Endpoints In Diabetes “The Pink Sheet” Apr. 7, 2014Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec “The Pink Sheet” DAILY Feb. 11, 2013Degludec Review Could Lead To New CV ... [Published Health News Daily - Apr 07 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Researchers at Diabetes Institute Report New Data on Diabetes

By a News Reporter-Staff News Editor at Diabetes Week -- New research on Diabetes is the subject of a report. According to news reporting originating in La Jolla, California , by NewsRx journalists, research stated, "Insulin degludec (IDeg) is a new basal ... [Published 4 Traders - Apr 02 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Technical Committee denies permission to 19 clinical trial proposals recommended by NDACs

The Technical Committee and the Apex Committee, the two high-level panels to supervise the clinical trials sector, have denied clearance to several proposals of clinical trials of new drugs, including fixed dose combinations, medical devices and global ... [Published PharmaBiz - Mar 31 2014]
First reported Mar 23 2014 - Updated Mar 23 2014 - 1 reports

CHMP recommends nine new drugs

The latest set of opinions from advisors to the European Medicines Agency include recommendations to approve nine new medicines, including potential blockbuster offerings in diabetes and hepatitis C, plus a drug for a sub-type of ovarian cancer and the ... [Published Pharma Times - Mar 23 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 3 reports

Tresiba and Victoza Receive CHMP Decisions for Expanded Use

Two products for the treatment of type 2 diabetes, insulin degludec ( Tresiba ) and liraglutide ( Victoza ), both from Danish drug firm Novo Nordisk, have this week been given positive opinions for expanded use by the European Medicines Agency's (EMA) ... [Published American Journal of Public Health - Mar 21 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Adocia announces positive results from BioChaperone combo, a combination of long-acting insulin glargine and fast-acting insulin lispro

Adocia, a biotech company specialized in the development of innovative formulations of already-approved therapeutic proteins with a strong expertise on insulins,  announces positive final results for the first clinical trial on its innovative formulation ... [Published PharmaBiz - Mar 21 2014]
First reported Mar 17 2014 - Updated Mar 17 2014 - 1 reports

Novo Nordisk unveils plans for $100m API plant

Novo Nordisk says it will invest around $100m in a new pilot facility to make the active pharmaceutical ingredients (APIs) for its pipeline of diabetes drug candidates.The 2,700 sq. m. purification facility - based at the Danish drugmaker's main Bagsvaerd ... [Published Pharmafocus - Mar 17 2014]
First reported Feb 06 2014 - Updated Feb 06 2014 - 1 reports

Human medicines European public assessment report (EPAR): Ryzodeg, insulin degludec / insulin aspart, Revision: 2, Authorised

Entities: Insulin, Degludec, Ryzodeg
First reported Dec 04 2013 - Updated Dec 04 2013 - 1 reports

Novo's IDegLira shows better blood sugar control in Phase III trial

Novo Nordisk has said that a Phase III trial of its diabetes drug IDegLira showed better control of blood sugar levels (HbA1c) compared to long-acting insulin Tresiba.IDegLira is a once-daily, single administration combination of insulin degludec Tresiba ... [Published Pharmaceutical Business Review - Dec 04 2013]
Entities: Insulin, Degludec, Phase III

Quotes

...According to news reporting originating in La Jolla, California , by NewsRx journalists, research stated, "Insulin degludec (IDeg) is a new basal insulin in development with a flat, ultra-long action profile that may permit dosing using a simplified titration algorithm with less frequent self-measured blood glucose (SMBG) measurements and more simplified titration steps than currently available basal insulins. This 26-week, multi-center, open-label, randomized, treat-to-target study compared the efficacy and safety of IDeg administered once-daily in combination with metformin in insulin-naive subjects with type 2 diabetes using two different patient-driven titration algorithms: a 'Simple' algorithm, with dose adjustments based on one pre-breakfast SMBG measurement (n=111) versus a 'Step-wise' algorithm, with adjustments based on three consecutive pre-breakfast SMBG values (n=111)."
The full indication for Victoza now reads as follows: "Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycemic"
"This is excellent news for patients with type 2 diabetes and their physicians. The update expands the options physicians have to individualise therapy for their patients and help them achieve glycaemic targets, especially if they have concerns about hypoglycaemia and weight gain" said Professor Chantal Mathieu
" Use of Tresiba in combination with GLP-1 receptor agonists in patients with type 2 diabetes mellitus"

More Content

All (14) | News (13) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
GSK glimepiride/atorvastatin fixed dose combina... [Published PR inside - Apr 14 2014]
FDA: No Decision On CV Outcomes Trial For Afrezza [Published Health News Daily - Apr 07 2014]
Researchers at Diabetes Institute Report New Da... [Published 4 Traders - Apr 02 2014]
Technical Committee denies permission to 19 cli... [Published PharmaBiz - Mar 31 2014]
CHMP recommends nine new drugs [Published Pharma Times - Mar 23 2014]
Tresiba and Victoza Receive CHMP Decisions for ... [Published American Journal of Public Health - Mar 21 2014]
Tresiba® and Victoza® Receive Positive Opinions... [Published ADVFN India - Mar 21 2014]
Tresiba® and Victoza® Receive Positive Opinions... [Published ADVFN UK - Mar 21 2014]
Pending EC decision: Tresiba, insulin degludec... [Published European Medicines Agency - Mar 21 2014]
Adocia announces positive results from BioChape... [Published PharmaBiz - Mar 21 2014]
Novo Nordisk unveils plans for $100m API plant [Published Pharmafocus - Mar 17 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
Novo's IDegLira shows better blood sugar contro... [Published Pharmaceutical Business Review - Dec 04 2013]
Novo Nordisk launches Tresiba for type1, type 2... [Published PharmaBiz - Sep 02 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 06 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.